Diabetes is a proinflammatory state: a translational perspective

References

• American College of Endocrinology. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr. Pract.8(Suppl. 1), 5–11 (2002).
   PubMedGoogle Scholar
• Narayan KM, Boyle JP, Thompson TJ et al. Lifetime risk for diabetes mellitus in the United States. JAMA290, 1884–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. US Dept of Health and Human Services, GA, USA 2005.
   Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care14, 173–194 (1991).
   PubMed Web of Science ®Google Scholar
• Vaccaro O, Eberly LE, Neaton JD et al. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch. Intern. Med.164, 1438–1443 (2004).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339, 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA265, 627–631 (1991).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339, 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA241, 2035–2038 (1979).
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16, 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature444(7121), 881–887 (2006).
   PubMed Web of Science ®Google Scholar
• Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem.54(1), 24–38 (2008).
   PubMed Web of Science ®Google Scholar
• Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res.91(4), 281–291 (2002).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin. Chem.55(2), 229–238 (2009).
   PubMed Web of Science ®Google Scholar
• Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol.49(21), 2129–2138 (2007).
   PubMed Web of Science ®Google Scholar
• Pickup JC, Mattock MB, Chusney GD et al. NIDDM as a disease of the innate immune system – association of acute-phase reactants and interleukin-6 with metabolic syndrome. Diabetologia40, 1286–129 (1997).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Jialal I. α tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and Type 2 diabetic patients. Free Radic. Biol. Med.29(8), 790–792 (2000).
   PubMed Web of Science ®Google Scholar
• Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination. Surv. Atheroscler.168(2), 351–358 (2003).
   PubMed Web of Science ®Google Scholar
• Tan KC, Chow WS, Tam SC et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.87(2), 563–568 (2002).
   PubMed Web of Science ®Google Scholar
• Jager A, van Hinsbergh VW, Kostense PJ et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler. Thromb. Vasc. Biol.19(12), 3071–3078 (1999).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr. Opin. Lipidol.20(3), 182–189 (2009).
   PubMed Web of Science ®Google Scholar
• Folsom AR, Aleksic N, Catellier D et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am. Heart J.144(2), 233–238 (2002).
   PubMed Web of Science ®Google Scholar
• Tracy RP, Lemaitre RN, Psaty BM et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler. Thromb. Vasc. Biol.17(6), 1121–1127 (1997).
   PubMed Web of Science ®Google Scholar
• Bermudez EA, Rifai N, Buring J et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler. Thromb. Vasc. Biol.22(10), 1668–1673 (2002).
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Norrie J, Caslake MJ et al; West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes51(5), 1596–1600 (2002).
   PubMed Web of Science ®Google Scholar
• Thorand B, Lowel H, Schneider A et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. Arch. Intern. Med.163(1), 93–99 (2003).
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N et al. C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA286(3), 327–334 (2001).
   PubMed Web of Science ®Google Scholar
• Muntner P, He J, Chen J et al. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann. Epidemiol.14(9), 686–695 (2004).
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Festa A, D’Agostino RB Jr et al. Metabolic and inflammation variable clusters and prediction of Type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes53(7), 1773–1781 (2004).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Glaser N, Griffen S et al. Increased monocytic activity and biomarkers of inflammation in patients with Type 1 diabetes. Diabetes55(3), 774–779. (2006).
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Poland DC, van Dijk W et al. Plasma concentration of C-reactive protein is increased in Type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia42(3), 351–357 (1999).
   PubMed Web of Science ®Google Scholar
• Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in Type 1 diabetes – the EURODIAB Prospective Complications Study. Diabetologia48(2), 370–378 (2005).
   PubMed Web of Science ®Google Scholar
• Hayaishi-Okano R, Yamasaki Y, Katakami N et al. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with Type 1 diabetes. Diabetes Care25(8), 1432–1438 (2002).
   PubMed Web of Science ®Google Scholar
• Moreno PR, Murcia AM, Palacios IF et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation102(18), 2180–2184 (2000).
   PubMed Web of Science ®Google Scholar
• Burke AP, Kolodgie FD, Zieske A et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol.24(7), 1266–1271 (2004).
   PubMed Web of Science ®Google Scholar
• Rousselot DB, Bastard JP, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab.26, 163–176 (2000).
   PubMed Web of Science ®Google Scholar
• Kitahara M, Eyre H, Lynch R et al. Metabolic activity of diabetic monocytes. Diabetes29, 251–256 (1980).
   PubMed Web of Science ®Google Scholar
• Hill H, Hogan N, Rallison M et al. Functional and metabolic abnormalities of diabetic monocytes. Adv. Expt. Med. Biol.69, 621–627 (1980).
   Google Scholar
• Devaraj S, Cheung AT, Jialal I et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with Type 1 diabetes and their role in microvascular complications. Diabetes56(11), 2790–2796 (2007).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Glaser N, Griffen S et al. Increased monocytic activity and biomarkers of inflammation in patients with Type 1 diabetes. Diabetes55(3), 774–779 (2006).
   PubMed Web of Science ®Google Scholar
• Fuller CJ, Agil A, Lender D, Jialal I. Superoxide production and LDL oxidation by diabetic neutrophils. J. Diabetes Complications10(4), 206–210 (1996).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in Type 2 diabetic patients with and without macrovascular complications: the effect of α-tocopherol supplementation. Circulation102(2), 191–196 (2000).
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1-receptor antagonist treatment in Type 2 diabetes mellitus. Diabetes Care32(9), 1663–1668 (2009).
   PubMed Web of Science ®Google Scholar
• Desfaits A, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion and TNF production in NIDDM patients after gliclazide treatment. Diabetes Care21, 487–491 (1998).
   PubMed Web of Science ®Google Scholar
• Ross R. Cell biology of atherosclerosis. Ann. Rev. Physiol.57, 791–804 (1995).
   PubMed Web of Science ®Google Scholar
• Kim J, Berliner J, Natarajan R et al. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes43, 1103–1107 (1994).
   PubMed Web of Science ®Google Scholar
• Carantoni M, Abbasi F, Chu L et al. Adherence of mononuclear cells to endothelium in vitro is increased in patients with NIDDM. Diabetes Care20, 1462–1465 (1997).
   PubMed Web of Science ®Google Scholar
• Hoogerbrugge N, Verkerk A, Jacobs M et al. Hypertriglyceridemia enhances monocyte binding to endothelial cells in NIDDM. Diabetes Care3, 1122–1124 (1997).
   Google Scholar
• Hwang S, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1–1, ICAM-1–1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation96, 4219–4225 (1997).
   PubMed Web of Science ®Google Scholar
• Rohde LE, Lee RT, Jamocochian M et al. Circulating CAMs are correlated with ultrasound measurement of carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol.18, 1765–1770 (1998).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Roitman JB et al. Plasma concentration of soluble ICAM-1 and risks of future MI in apparently healthy men. Lancet351, 88–92 (1998).
   PubMed Web of Science ®Google Scholar
• Albertini JP, Valensi P, Lormeau B et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care21, 1008–1013 (1998).
   PubMed Web of Science ®Google Scholar
• Fasching P, Waldhausl W, Wagner OF. Elevated circulating adhesion molecules in NIDDM-potential mediators in diabetic macroangiopathy. Diabetologia39, 1242–1244 (1996).
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Sera Y, Abe Y et al. Serum concentrations of soluble vascular cell adhesion molecule-1 and E-selectin are elevated in insulin-resistant patients with Type 2 diabetes. Diabetes Care24, 1697–1698 (2001).
   PubMed Web of Science ®Google Scholar
• Mocco J, Choudhri TF, Mack WJ et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery48, 718–721 (2001).
   PubMed Web of Science ®Google Scholar
• Kulseng B, Vatten L, Espevik T. Soluble tumor necrosis factor receptors in sera from patients with insulin-dependent diabetes mellitus: relations to duration and complications of disease. Acta Diabetol.36(1–2), 99–105 (1999).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Hayden MS. New regulators of NF-κB in inflammation. Nat. Rev. Immunol.8(11), 837–848 (2008).
   PubMed Web of Science ®Google Scholar
• Sarkar FH, Li Y, Wang Z, Kong D. NF-κB signaling pathway and its therapeutic implications in human diseases. Int. Rev. Immunol.27(5), 293–319 (2008).
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Ramana KV. Focus on molecules: nuclear factor-κB. Exp. Eye Res.88(1), 2–3 (2009).
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Schiekofer S, Isermann B et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia42(2), 222–232 (1999).
   PubMed Web of Science ®Google Scholar
• Sebestjen M, Zegura B, Guzic-Salobir B et al. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia. Wien Klin. Wochenschr.113(3–4), 113–118 (2001).
   PubMed Web of Science ®Google Scholar
• Wiman B, Andersson T, Hallqvist J et al. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler. Thromb. Vasc. Biol.20(8), 2019–2023 (2000).
   PubMed Web of Science ®Google Scholar
• Eren M, Painter CA, Atkinson JB et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation106, 491–496 (2002).
   PubMed Web of Science ®Google Scholar
• Schafer K, Muller K, Hecke A et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler. Thromb. Vasc. Biol.23(11), 2097–2103 (2003).
   PubMed Web of Science ®Google Scholar
• Eitzman DT, Westrick RJ, Xu Z et al. PAI-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood96, 4212–4215 (2000).
   PubMed Web of Science ®Google Scholar
• Xiao Q, Danton MJ, Witte DP et al. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc. Natl Acad. Sci. USA94(19), 10335–10340 (1997).
   PubMed Web of Science ®Google Scholar
• Fujii S, Goto D, Zaman T et al. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. J. Atheroscler. Thromb.5(2), 76–81 (1998).
   PubMedGoogle Scholar
• Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch. Mal. Coeur. Vaiss.97(6), 673–678 (2004).
   PubMedGoogle Scholar
• Festa A, D’Agostino R Jr, Mykkanen L et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler. Thromb. Vasc. Biol.19(3), 562–568 (1999).
   PubMed Web of Science ®Google Scholar
• Li H, Sun B. Toll-like receptor 4 in atherosclerosis. J. Cell. Mol. Med.11(1), 88–95 (2007).
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol.7(3), 179–190 (2007).
   PubMed Web of Science ®Google Scholar
• Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr. Pharm. Des.12(32), 4229–4245 (2006).
   PubMed Web of Science ®Google Scholar
• Uematsu S, Akira S. Toll-like receptors and innate immunity. J. Mol. Med.84(9), 712–725 (2006).
   PubMed Web of Science ®Google Scholar
• Mullick AE, Tobias PS, Curtiss LK. Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol. Res.34(3), 193–209 (2006).
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Roles of Toll-like receptors in innate immune responses. Genes Cells6(9), 733–742 (2001).
   PubMed Web of Science ®Google Scholar
• Liu X, Ukai T, Yumoto H et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis196(1), 146–154 (2009).
   Web of Science ®Google Scholar
• Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest.115(11), 3149–3156 (2005).
   PubMed Web of Science ®Google Scholar
• Bjorkbacka H, Kunjathoor VV, Moore KJ et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med.10(4), 416–421 (2004).
   PubMed Web of Science ®Google Scholar
• Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem. Biophys. Res. Commun.346(3), 739–745 (2006).
   PubMed Web of Science ®Google Scholar
• Mohammad MK, Morran M, Slotterbeck B et al. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int. Immunol.18(7), 1101–1113 (2006).
   PubMed Web of Science ®Google Scholar
• Kim HS, Han MS, Chung KW et al. Toll-like receptor 2 senses β-cell death and contributes to the initiation of autoimmune diabetes. Immunity27(2), 321–323 (2007).
   PubMed Web of Science ®Google Scholar
• Wen L, Peng J, Li Z, Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J. Immunol.172(5), 3173–3180 (2004).
   PubMed Web of Science ®Google Scholar
• Park Y, Park S, Yoo E, Kim D, Shin H. Association of the polymorphism for Toll-like receptor 2 with Type 1 diabetes susceptibility. Ann. NY Acad. Sci.1037, 170–174 (2004).
   PubMed Web of Science ®Google Scholar
• Creely SJ, McTernan PG, Kusminski CM et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.292(3), E740–E774 (2007).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Dasu MR, Rockwood J et al. Increased Toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with Type 1 diabetes: further evidence of a proinflammatory state. J. Clin. Endocrinol. Metab.93(2), 578–583 (2008).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in Type 1 diabetes. Diabetologia52(8), 1665–1668 (2009).
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ. Res.89(12), 1092–1103 (2001).
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci.58(1), 4–43 (2001).
   PubMed Web of Science ®Google Scholar
• Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis137, S89–S95 (1998).
   PubMed Web of Science ®Google Scholar
• Varo N, de Lemos JA, Libby P et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation108(9), 1049–1052 (2003)
   PubMed Web of Science ®Google Scholar
• Varo N, Vicent D, Libby P et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation107(21), 2664–2669 (2003).
   PubMed Web of Science ®Google Scholar
• Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selection, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation109(21), 2524–2528 (2004).
   PubMed Web of Science ®Google Scholar
• Jinchuan Y, Zonggui W, Jinming C et al. Upregulation of CD40–CD40 ligand system in patients with diabetes mellitus. Clin. Chim. Acta339(1–2), 85–90 (2004).
   PubMed Web of Science ®Google Scholar
• Venugopal SK, Devaraj S, Yang T, Jialal I. α-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes51(10), 3049–3055 (2002).
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Jialal I. High glucose induces IL-1β expression in human monocytes: mechanistic insights. Am. J. Physiol. Endocrinol. Metab.293(1), E337–E346 (2007)
   Web of Science ®Google Scholar
• Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase C-α and -β. Diabetes54(1), 85–89 (2005).
   PubMed Web of Science ®Google Scholar
• Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes52(5), 1256–1264 (2003).
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Bolick DT, Hatley ME et al. Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes. J. Biol. Chem.279(30), 31930–31936 (2004).
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Zhao L et al. High glucose induces Toll-like receptor expression in human monocytes: mechanism of activation. Diabetes57(11), 3090–3098 (2008).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Jialal I. Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway. Cytokine47(1), 6–10 (2009).
   PubMed Web of Science ®Google Scholar
• Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance – a mini-review. Gerontology55(4), 379–386 (2009).
   PubMed Web of Science ®Google Scholar
• Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J. Clin. Endocrinol. Metab.93(11 Suppl. 1), S64–S73 (2008).
   PubMed Web of Science ®Google Scholar
• Surmi BK, Hasty AH. Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol.3(5), 545–556 (2008).
   PubMed Web of Science ®Google Scholar
• Greenfield JR, Samaras K, Jenkins AB et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation109(24), 3022–3028 (2004).
   PubMed Web of Science ®Google Scholar
• Sam S, Haffner S, Davidson MH et al. Relation of abdominal fat depots to systemic markers of inflammation in Type 2 diabetes. Diabetes Care32(5), 932–937 (2009).
   PubMed Web of Science ®Google Scholar